JAK2 and essential thrombocythemia: Platelets from ET patients carrying JAK2 mutations exhibited stronger responses to TRAP6 stimulation than those with CALR mutations, as indicated by higher P-selectin exposure and αIIbβ3 integrin activation, which is consistent with the lower risk of thrombosis reported in CALR-mutant patients compared with JAK2 (Table 3 and Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI172256DS1) (20).